D.A. Davidson & Co’s Viking Therapeutics VKTX Stock Holding History

D.A. Davidson & Co’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,480	Closed	-$301K	–	1504
2024 Q4	$301K	Buy	7,480 +3,636	+95%	+$207K	﹤0.01%	1200
2024 Q3	$243K	Buy	+3,844	New	+$226K	﹤0.01%	1246
2021 Q4	–	Sell	-12,500	Closed	-$79K	–	1310
2021 Q3	$79K	Hold	12,500	–	–	﹤0.01%	1188
2021 Q2	$75K	Buy	12,500 +1,000	+9%	+$5.94K	﹤0.01%	1170
2021 Q1	$73K	Buy	+11,500	New	+$80.9K	﹤0.01%	1136
2019 Q4	–	Sell	-16,150	Closed	-$111K	–	1063
2019 Q3	$111K	Sell	16,150 -150	-0.9%	-$1.11K	﹤0.01%	960
2019 Q2	$135K	Buy	16,300 +580	+4%	+$4.96K	﹤0.01%	930
2019 Q1	$156K	Buy	15,720 +2,065	+15%	+$17.3K	﹤0.01%	1062
2018 Q4	$104K	Buy	+13,655	New	+$163K	﹤0.01%	1048

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.A. Davidson & Co's VKTX Position: Q1 2025 in Review

D.A. Davidson & Co sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 7,480 shares — an estimated $301K sold.

D.A. Davidson & Co first reported a position in VKTX in Q4 2018 and held it in 9 quarters. The position peaked at $301K in Q4 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

D.A. Davidson & Co reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
D.A. Davidson & Co sold 7,480 Viking Therapeutics shares in Q1 2025, an estimated $301K.
D.A. Davidson & Co first reported a position in Viking Therapeutics in Q4 2018 and held it in 9 quarters.
D.A. Davidson & Co's Viking Therapeutics position peaked at $301K in Q4 2024.
372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on D.A. Davidson & Co's 13F filing for Q1 2025, filed 28 Apr 2025.